Loading…
Stevanato Group S.p.A. is projected to rise to $19.85 by 2027, a +10% move from its current price of $18.07. STVN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $17.74 | $18.07 | $18.41 | 0.00% |
| May 30 | $17.60 | $18.07 | $18.55 | 0.00% |
| May 31 | $17.49 | $18.07 | $18.66 | 0.00% |
| Jun 1 | $17.41 | $18.07 | $18.76 | 0.00% |
| Jun 2 | $17.33 | $18.07 | $18.84 | 0.00% |
| Jun 3 | $17.26 | $18.07 | $18.91 | -0.01% |
| Jun 4 | $17.20 | $18.07 | $18.98 | -0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.20 | $18.07 | $18.98 | -0.01% |
| Week 2 | $16.85 | $18.07 | $19.37 | -0.01% |
| Week 3 | $16.59 | $18.07 | $19.68 | -0.02% |
| Week 4 | $16.37 | $18.07 | $19.94 | -0.03% |
| Week 5 | $16.18 | $18.06 | $20.17 | -0.03% |
| Week 6 | $16.01 | $18.06 | $20.38 | -0.04% |
| Week 7 | $15.85 | $18.06 | $20.58 | -0.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers.
The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Stevanato Group S.p.A. trades as STVN. The current price is $18.01 per share, and the market capitalization stands at $4.92B. The stock is ranked 1354 by market capitalization. A 30-day range of $15.80 to $20.52 provides context for recent price action.
A major floor 28.0% below — a decisive break under it would weaken the trend.
The nearest floor, 18.4% below — buyers have tended to step in here.
The nearest ceiling, 5.1% above — a clean break opens room to run.
A major ceiling 19.1% above — clearing it would confirm fresh momentum.
Key STVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of STVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.93 | Buy | $17.95 | Buy |
| MA 10 | $17.86 | Buy | $17.88 | Buy |
| MA 20 | $17.87 | Buy | $17.55 | Buy |
| MA 50 | $15.94 | Buy | $16.81 | Buy |
| MA 100 | $16.49 | Buy | $17.32 | Buy |
| MA 200 | $20.07 | Sell | $18.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.82 | Neutral |
| Stoch RSI (14) | 50.10 | Neutral |
| CCI (20) | 38.79 | Neutral |
| Williams %R (14) | -22.11 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | -0.88 | Sell |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 77.89 | Neutral |
| TRIX (15) | 0.61 | Buy |
| Awesome (5,34) | 1.16 | Buy |
| Ultimate (7,14,28) | 50.05 | Neutral |
| Momentum (10) | -0.17 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 18.05 | Buy |
| ADX (14) | 27.54 | Buy |
| ATR (14) | 0.26 | Info |
Technical momentum remains neutral with RSI(14) at 60. The stock trades above the 50-day simple moving average of $15.82 but below the 200-day simple moving average of $20.13. The current price of $18.01 sits between these moving averages, indicating mixed near-term momentum.
Support is at $13.81 and resistance at $19.00. The 30-day range is $15.80–$20.52, and annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.43 | $18.07 | $23.14 | 0% | Neutral | |
| $16.22 | $19.85 | $25.44 | +10% | Neutral | |
| $15.64 | $19.50 | $25.63 | +8% | Neutral | |
| $17.36 | $21.97 | $29.49 | +22% | Bullish | |
| $19.67 | $25.22 | $34.45 | +40% | Bullish | |
| $21.90 | $28.42 | $39.42 | +57% | Bullish | |
| $23.58 | $30.95 | $43.53 | +71% | Bullish | |
| $23.79 | $31.54 | $44.93 | +75% | Bullish | |
| $24.85 | $33.28 | $47.97 | +84% | Bullish | |
| $25.64 | $34.66 | $50.51 | +92% | Bullish | |
| $36.17 | $50.99 | $77.85 | +182% | Bullish | |
| $59.42 | $89.81 | $146.96 | +397% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $13.43 | $18.07 | $21.21 | +0.00% |
| June 2026 | $15.75 | $18.37 | $21.85 | +1.68% |
| July 2026 | $15.39 | $18.05 | $21.67 | -1.74% |
| August 2026 | $15.31 | $18.05 | $21.82 | -0.05% |
| September 2026 | $15.65 | $18.52 | $22.52 | +2.61% |
| October 2026 | $15.67 | $18.60 | $22.74 | +0.44% |
| November 2026 | $15.47 | $18.42 | $22.63 | -0.98% |
| December 2026 | $15.71 | $18.75 | $23.14 | +1.83% |
Click any year to see its month-by-month STVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The STVN price prediction for 2026 points to an average of $18.07 (low $13.43, high $23.14) — a potential gain of 0% on today's $18.07. Price action looks broadly range-bound.
In 2027, STVN is projected to trade between $16.22 and $25.44, averaging $19.85 — a potential gain of +10% from today's $18.07. That is up +10% on the projected 2026 average. A consolidation phase looks the most probable path here.
Stevanato Group S.p.A.'s 2028 outlook centres on $19.50, within a $15.64 to $25.63 range. That is -2% versus the projected 2027 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2029, STVN could reach as high as $29.49, with a base case around $21.97 and support toward $17.36 — roughly +22% from $18.07. Buyers look set to stay in control over this stretch.
Expect STVN to range from $19.67 to $34.45 through 2030. The $25.22 average target implies a +40% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The STVN price prediction for 2031 points to an average of $28.42 (low $21.90, high $39.42) — a potential gain of +57% on today's $18.07. Buyers look set to stay in control over this stretch.
In 2032, STVN is projected to trade between $23.58 and $43.53, averaging $30.95 — a potential gain of +71% from today's $18.07. That is up +9% on the projected 2031 average. Momentum favours further upside here.
Stevanato Group S.p.A.'s 2033 outlook centres on $31.54, within a $23.79 to $44.93 range. That is up +2% on the projected 2032 average. That marks a +75% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, STVN could reach as high as $47.97, with a base case around $33.28 and support toward $24.85 — roughly +84% from $18.07. Momentum favours further upside here.
Expect STVN to range from $25.64 to $50.51 through 2035. The $34.66 average target implies a +92% move from current prices. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The STVN price prediction for 2040 points to an average of $50.99 (low $36.17, high $77.85) — a potential gain of +182% on today's $18.07. Momentum favours further upside here.
In 2050, STVN is projected to trade between $59.42 and $146.96, averaging $89.81 — a potential gain of +397% from today's $18.07. That is up +76% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in STVN today (≈ 55.340343 STVN) could be worth
$4,970.37
+$3,970.37 (+397%) by 2050 · US Dollar
Based on the average projected STVN price of $89.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in STVNwould be worth at today's price.
$1,000 invested in STVN on May 27, 2025 (≈ 43.782837 STVN) would be worth
$791.16
-$208.84 (-20.9%) today · 0.79× · US Dollar
Based on a STVN entry price of $22.84 vs. today's $18.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.75 | $1,018.03 | +1.8% |
| 1 month ago | $16.18 | $1,116.81 | +11.7% |
| 3 months ago | $15.31 | $1,180.27 | +18.0% |
| 6 months ago | $23.36 | $773.54 | -22.6% |
| 1 year ago | $22.84 | $791.16 | -20.9% |
| All time (4.9y) ago | $19.67 | $918.66 | -8.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our STVN forecast.
Our base-case forecast reaches $36.00 around 2040.
Implied market cap at $36.00: $1.79B
The multi-year forecast shows a bullish trajectory after 2028, with 2029 averaging $22.17 and a 23.1% ROI, rising to 2030 averaging $25.38 with a 40.9% ROI, and 2031 averaging $28.50 with a 58.2% ROI. It continues higher through 2032 at an average of $31.24 (73.5% ROI) and 2033 at $31.70 (76% ROI), then 2034 at $33.46 (85.8% ROI) and 2035 at $35.08 (94.8% ROI). By 2040, the average is projected to $51.43 with a 185.6% ROI, and by 2050 the average reaches $91.44 with a 407.7% ROI.
The forecast sentiment is bullish from 2029 onward, with NEUTRAL in 2026–2028. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast shows an average price of $25.38 with a min of $19.67, a max of $34.94, and a ROI of 40.9% in 2030; sentiment is BULLISH.
The forecast depicts a long-run bullish trajectory, with 2029–2035 showing rising averages and higher ROI (e.g., 2029 avg $22.17, ROI 23.1%; 2030 avg $25.38, ROI 40.9%; 2031 avg $28.50, ROI 58.2%; 2032 avg $31.24, ROI 73.5%; 2033 avg $31.70, ROI 76%; 2034 avg $33.46, ROI 85.8%; 2035 avg $35.08, ROI 94.8%). From 2040 onward, the forecast continues higher (2040 avg $51.43, ROI 185.6%; 2050 avg $91.44, ROI 407.7%). These are estimates, not guarantees.
Yes. The forecast shows a 2040 average of $51.43 with a max of $79.52, and a 2040 min of $36.06, indicating a potential to reach or exceed $50 by 2040.
Current price is $18.01 per share. Market capitalization is $4.92B. The stock rank is 1354.
Healthcare. The description notes operations and products across biopharma and diagnostic solutions and engineering, with a founding date of 1949 and headquarters in Piombino Dese, Italy, and that it is a subsidiary of Stevanato Holding S.R.L.
Stevanato Group S.p.A. Community Discussion
0Share your Stevanato Group S.p.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.